BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX has expanded the application of its Anchored Multiplex PCR (AMP™) technology to include DNA variant detection with the VariantPlex™ Solid Tumor Panel. The VariantPlex Solid Tumor panel is a targeted next-generation sequencing (NGS)-based assay to detect somatic variants in 67 cancer-associated genes. The addition of the VariantPlex product line combined with Archer’s existing FusionPlex™ line of RNA-based fusion detection assays demonstrates the company’s commitment to bringing translational sequencing applications to the broader sequencing community.
About the VariantPlex NGS Assays
Archer VariantPlex assays utilize AMP chemistry to capture and amplify sections of the genome frequently mutated in cancers. AMP libraries have greater target recovery from short fragments, making the technology ideal for low-input FFPE samples. Molecular barcoding of input molecules enables quantitative analysis, de-duplication and error correction via Archer Analysis bioinformatics software, resulting in unparalleled confidence in mutation calling. VariantPlex assays detect single nucleotide variants (SNVs), insertion/deletions (indels) and copy number variations (CNV) in a single assay.
VariantPlex assays use Archer’s targeted NGS mutation detection workflow that includes library preparation, analysis and reporting. Archer assays use a simple and rapid lyophilized workflow optimized to minimize hands-on time and risk of contamination during library preparation. After sequencing on the Illumina™ platform, the complementary Archer Analysis software provides comprehensive analysis with embedded QC metrics and read visualization to accurately detect and report known and novel fusions, SNPs, indels and CNVs.
Comprehensive Fusion, SNP, Indel, and CNV Detection
Together, the FusionPlex and VariantPlex Solid Tumor panels provide a comprehensive, targeted sequencing approach to detecting driver mutations in solid tumors. These panels can be used in parallel for the comprehensive detection of clinically relevant fusions, SNPs, indels and CNVs from a single, low-input FFPE sample. Labs can go from sample-to-sequence in under one day, enabling total turnaround time of 3-5 days from sample extraction through data processing. With the FusionPlex and VariantPlex parallel workflow, Archer provides the tools for in-house, comprehensive sample testing for all relevant mutations, reducing necessary input amounts, costly send outs and long turn-around times.
About ArcherDX
ArcherDX addresses the bottlenecks associated with using next-generation sequencing in translational research by offering a robust platform for targeted sequencing applications.
By combining proprietary Anchored Multiplexed PCR (AMP) chemistry and easy-to-use, lyophilized reagents, ArcherDX technology generates highly enriched sequencing libraries to detect gene fusions, SNPs, indels and CNVs. Complemented by the Archer suite of bioinformatics software and readily accessible reports, ArcherDX technology dramatically enhances complex mutation identification and discovery.
ArcherDX is headquartered in Boulder, Colo., and maintains manufacturing operations in Beverly, Mass. www.archerdx.com
Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.